Konstantin Dragnev, MD

practices at Dartmouth Cancer Center

Published Articles (1)

Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention

September 8, 2026

Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.